Denali Therapeutics Inc.
Clinical trials sponsored by Denali Therapeutics Inc., explained in plain language.
A biopharmaceutical company developing therapies for neurodegenerative diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for rare dementia: experimental drug DNL593 enters human trials Results expected Dec 2026 (estimated)
- New Alzheimer's drug enters early human testing Results expected Feb 2027 (estimated)
- Promising new drug targets genetic Parkinson's in early trial Results expected Mar 2027 (estimated)
- New hope for hunter syndrome: Long-Term drug trial launches Results expected Jun 2027 (estimated) May already have reported ↗
-
New enzyme therapy aims to reach the brain in MPS II
Disease control OngoingResearchers are testing tividenofusp alfa (DNL310), an experimental enzyme replacement therapy, against the standard treatment idursulfase in children and young adults with mucopolysaccharidosis type II (MPS II). The study includes participants with and without brain involvement,…
Phase 2/3 • Sponsor: Denali Therapeutics Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for kids with rare brain disease: drug targets toxic buildup
Disease control OngoingThis study tests a drug called DNL126 in 20 children with Sanfilippo syndrome type A, a rare genetic disorder that causes brain damage. The drug is given through a vein and aims to reduce harmful substances in the brain and body. The trial lasts about 6 months, with options to co…
Phase 1/2 • Sponsor: Denali Therapeutics Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for hunter syndrome: Long-Term drug trial launches
Disease control By invitation onlyThis study looks at the long-term safety and effects of an experimental drug called DNL310 for people with Hunter syndrome (MPS II), a rare genetic disorder. About 99 participants who completed earlier studies will receive the drug for up to 5 years. Researchers will monitor side…
Phase 2/3 • Sponsor: Denali Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Promising new drug targets genetic Parkinson's in early trial
Disease control OngoingThis study tests an experimental drug called BIIB122 in 50 people who have a specific genetic form of Parkinson's disease (LRRK2-PD). The main goal is to check the drug's safety and how it affects certain markers in the blood and urine over 12 weeks. Participants are randomly ass…
Phase 2 • Sponsor: Denali Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for rare dementia: experimental drug DNL593 enters human trials
Disease control OngoingThis study tests an experimental drug called DNL593 in healthy volunteers and people with frontotemporal dementia (FTD), a rare brain disease that causes personality changes and memory loss. The trial aims to check if the drug is safe, how the body processes it, and whether it mi…
Phase 1/2 • Sponsor: Denali Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC